Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.

Abstract: A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor.

Abstract: The anti-inflammatory zinc(II) complex, viz., crystalline bis(chloro)-(N,N?-(2,2-dimethylpropane-1,3-diyl)bis(1-(2-chlorophenyl)-methanimine))-zinc zinc(II) complex, may be used as an anti-inflammatory. The compound has the formula: This complex is prepared by reaction of a Schiff base, namely, N,N?-bis(2-chlorobenzylidene)-2,2-dimethylpropane-1,3-diamine, with zinc chloride in alcohol to form a precipitate, which is removed by filtration, followed by slow evaporation of the filtrate to obtain the crystalline product. In vivo testing showed that the above zinc(II) complex exhibited good anti-inflammatory effect. It is thought that the present zinc-based anti-inflammatory avoids the gastrointestinal side effects of conventional NSAIDs due to the coordinated zinc complex.

Abstract: Methods and compositions disclosed herein generally relate to methods, compounds, and compositions for treating myeloproliferative neoplasms (MPNs) or a symptom thereof, comprising administering, to a subject in need thereof, a therapeutically effective amount of a DUSP1 inhibiting compound, or of a pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof. Embodiments of the invention also relate to use of a compound, or pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof, for the preparation of a composition or medicament for the treatment of a myeloproliferative neoplasm (MPN), wherein the compound is an inhibitor of DUSP1.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: The present invention relates to a wool treatment process and to a wool product produced by the wool treatment process. In particular, the invention relates to a wool treatment process that produces a wool product with increased absorbency properties and to a wool product that has increased absorbency properties.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: A pharmaceutically acceptable composition and method for solid tumor therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, and (b) an inhibitor of Dusp-1, and optionally (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for solid tumors.

Abstract: The dual-band MIMO antenna system includes antenna elements arranged on a printed circuit board. For the plurality of antennas on the board, the opposing antennae are arranged in mirror-image fashion. Each antenna has a first elongate vertical element connected to and extending vertically from one end of a horizontal element. A second, shorter elongate vertical element is disposed proximate an opposite end of the horizontal element and extends upward therefrom in parallel with the first elongate member. First (feed) and second (short) stubby vertical elements are disposed on the horizontal element proximate the second elongate member and extend downward from the horizontal element. A ground plane is formed on the opposite face of the printed circuit board.

Abstract: A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of BCR-ABL tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for leukemia.

Abstract: The dual-band MIMO antenna system includes antenna elements arranged on a printed circuit board. For the plurality of antennas on the board, the opposing antennae are arranged in mirror-image fashion. Each antenna has a first elongate vertical element connected to and extending vertically from one end of a horizontal element. A second, shorter elongate vertical element is disposed proximate an opposite end of the horizontal element and extends upward therefrom in parallel with the first elongate member. First (feed) and second (short) stubby vertical elements are disposed on the horizontal element proximate the second elongate member and extend downward from the horizontal element. A ground plane is formed on the opposite face of the printed circuit board.

Abstract: A computing device receives selection of television content from a device associated with a user, and collects metadata associated with the selected television content. The computing device also collects information associated with commercials associated with the television content, and determines an interactive product/service listing based on the collected metadata and commercial information. The device further provides the interactive product/service listing to the device for display to the user.

Abstract: The invention relates to a porous keratin construct material comprising keratin protein for use in wound healing applications. The porous keratin construct is capable of bio-absorbing into a wound to promote wound healing. The rate at which the construct bio-absorbs into the wound may be controlled altered by controlling the degree of disulfide cross-linking between the keratin proteins in the porous keratin construct. The invention is also related to a method of making the porous keratin construct.

Abstract: A computing device receives selection of television content from a device associated with a user, and collects metadata associated with the selected television content. The computing device also collects information associated with commercials associated with the television content, and determines an interactive product/service listing based on the collected metadata and commercial information. The device further provides the interactive product/service listing to the device for display to the user.

Abstract: The application describes materials derived from keratin proteins in combination with polymers, either as intimate mixtures with water soluble polymers, or as chemically bound copolymers. The keratin protein is a specific keratin protein fraction, and is preferably intact, s-sulfonated and from the intermediate filament protein family. The application also describes the process for production of these materials.

Abstract: The invention relates to a would care product that provides a biochemical environment around a wound to promote wound healing. The wound care product includes a keratin protein fraction material in which the protein fraction is intact, is from the intermediate filament protein family or the high sulfur protein family and in which the protein fraction is S-sulfonated. The invention also described a method of making a wound care product.

Abstract: The present invention is directed to methods to determine the likelihood of therapeutic effectiveness of a farnesyl transferase inhibitor (FTI). The method comprises determining whether the gene encoding the farnesyl transferase beta subunit (FNTB) of said patient comprises at least one nucleic acid variance that causes an alteration in an amino acid residue. The change in the amino acid residue is associated with resistance to a FTI. The absence of at least one variance indicates that the FTI is likely to be effective.

Abstract: The invention relates to a porous keratin construct material comprising keratin protein for use in wound healing applications. The porous keratin construct is capable of bio-absorbing into a wound to promote wound healing. The rate at which the construct bio-absorbs into the wound may be controlled altered by controlling the degree of disulfide cross-linking between the keratin proteins in the porous keratin construct. The invention is also related to a method of making the porous keratin construct.

Abstract: A porous keratin construct for use in wound healing is disclosed. The porous keratin construct may be used standing alone or in combination with a synthetic foam backing layer. Either the porous keratin construct or the porous keratin construct and synthetic foam combination may be used in a wound therapy such as negative pressure wound therapy.

Abstract: The invention relates to a would care product that provides a biochemical environment around a wound to promote wound healing. The wound care product includes a keratin protein fraction material in which the protein fraction is intact, is from the intermediate filament protein family or the high sulfur protein family and in which the protein fraction is S-sulfonated. The invention also described a method of making a wound care product.